RxDoctor Payments Data

Connie Ash, APRN

Family · Blytheville, ARNPI 1720402464

Payments from drug & device makers

$985in general payments, 2019–2025

Across 31 payments — averaging $31.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$242
  • AstraZeneca$230
  • Astellas Pharma US Inc$118
  • Lilly USA, LLC$94
  • Abbott$63
  • Exact Sciences$58
  • plus $180 from 6 others

What the payments were for

  • Food & beverage$88690%
  • Education$9910%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$985 in reported general payments places this provider in the 65th percentile of 2,103 family providers in Arkansas.

See all family providers in Arkansas

Medicare billing

Part B allowed, 2024
$26,762
Medicare patients
108
Services billed
832

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide67$69,409
JanuviaSitagliptin Phosphate48$34,521
LinzessLinaclotide49$34,286
EliquisApixaban49$33,886
JanumetSitagliptin Phos/Metformin Hcl55$31,460
FarxigaDapagliflozin Propanediol45$30,574
TrulicityDulaglutide26$28,434
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$17,709
EntrestoSacubitril/Valsartan16$17,657
JardianceEmpagliflozin13$14,921
Tresiba Flextouch U-100Insulin Degludec16$9,840
Breztri AerosphereBudesonide/Glycopyr/Formoterol12$6,578
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog14$4,502
Albuterol Sulfate HfaAlbuterol Sulfate138$4,110
Pregabalin59$3,661

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere$230$37,15257 claims
AbbVieLinzess$13$34,28649 claims
Lilly USA, LLCTrulicity$94$28,43426 claims
GSKTrelegy Ellipta$242$17,70920 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,103 family providers in Arkansas.

Other family in Blytheville

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →